.jpg)
Exploring the Tumor Microenvironment: Innovations and Challenges in Enhancing Immunotherapy Efficacy
Submission Deadline: 1 Dec 2025
Special Issue Information
Dear Colleagues,
The tumor microenvironment (TME) plays a crucial role in shaping the efficacy of immunotherapy treatments for cancer. This dynamic and complex ecosystem, which includes tumor cells, cancer stem cells, immune cells, stromal components, and extracellular matrix, can significantly influence tumor progression and response to therapy. Recent research highlights both the opportunities and challenges associated with targeting the TME to improve immunotherapy outcomes. Understanding the interplay between the TME and immune response is essential for advancing personalized immunotherapy.
We invite authors to contribute to our upcoming topics, focusing on the intricate interplay between the TME and therapeutic strategies aimed at enhancing immune responses against cancer. Topics of interest include, but are not limited to:
• The role of the TME in shaping immune responses and influencing immunotherapy efficacy
• Molecular mechanism of the tumor ecosystem
• Innovations in targeting any component of TME to enhance treatment responses
• Advances in novel therapeutic approaches and technologies for TME modulation
• Biomarkers and profiling techniques for assessing TME characteristics and predicting therapeutic outcomes
Dr. Rada Amin Ali and Dr. Terry Lichtor
Guest Editors
Keywords
- tumor microenvironment
- immunotherapy
- immune system
- precision medicine
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://www.discovmed.com/Journalx_dm/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.
Published Papers (6)
DM 2026, 38(207), 1007-1026; https://doi.org/10.24976/Discov.Med.202638207.81
(This article belongs to the Special Issue Exploring the Tumor Microenvironment: Innovations and Challenges in Enhancing Immunotherapy Efficacy)
DM 2026, 38(205), 368-388; https://doi.org/10.24976/Discov.Med.202638205.31
(This article belongs to the Special Issue Exploring the Tumor Microenvironment: Innovations and Challenges in Enhancing Immunotherapy Efficacy)
DM 2026, 38(205), 343-356; https://doi.org/10.24976/Discov.Med.202638205.29
(This article belongs to the Special Issue Exploring the Tumor Microenvironment: Innovations and Challenges in Enhancing Immunotherapy Efficacy)
DM 2025, 37(201), 2159-2177; https://doi.org/10.24976/Discov.Med.202537201.184
(This article belongs to the Special Issue Exploring the Tumor Microenvironment: Innovations and Challenges in Enhancing Immunotherapy Efficacy)
DM 2025, 37(200), 1721-1744; https://doi.org/10.24976/Discov.Med.202537200.150
(This article belongs to the Special Issue Exploring the Tumor Microenvironment: Innovations and Challenges in Enhancing Immunotherapy Efficacy)
DM 2025, 37(192), 166-181; https://doi.org/10.24976/Discov.Med.202537192.14
(This article belongs to the Special Issue Exploring the Tumor Microenvironment: Innovations and Challenges in Enhancing Immunotherapy Efficacy)
Guest Editors
Rada Amin Ali
Terry Lichtor
.jfif)